You just read:

Ortho Dermatologics Announces Two-Year Findings From Pivotal Phase 3 Study Of SILIQ™ (brodalumab) Injection Data Demonstrating Long-Term Efficacy Profile

News provided by

Valeant Pharmaceuticals International, Inc.

Oct 12, 2017, 08:00 ET